VIVA BIOTECH HOLDINGS / PORDA HAVAS
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future 2024-03-28 22:46
Latest Updates of Viva Biotech's Portfolio Companies 2024-03-06 19:33
Latest Updates of Viva's Portfolio Companies 2023-12-04 17:55
Viva Biotech Secures Approximately US$ 210 Million Funding 2023-11-20 20:04
Latest Updates of Viva's Portfolio Companies 2023-09-26 21:06
Viva Biotech (1873.HK) Announces 2023 Interim Results：Solid Growth in Main Business, Significant Rebound in Profitability 2023-08-29 22:38
Latest Updates of 7 Viva's Portfolio Companies 2023-07-28 19:31
Viva Biotech's Portfolio Company Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs 2023-07-20 19:15
Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis 2023-07-18 15:00
Latest Updates of 9 Viva's Portfolio Companies 2023-06-02 18:51
Viva Biotech's Recent Conferences & Events Review 2023-05-05 19:58
Viva Biotech Attended SAPA-China 2023-04-13 11:33
Latest Updates of 6 Viva's Portfolio Companies 2023-04-04 19:39
Viva Biotech Announced 2022 Annual Results: 2023-03-31 00:25
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies 2022-12-02 18:23
Portfolio Highlights: Clinical and Financial Updates of ABM, F5, AceLink, HAYA, Regenacy, and Arthrosi 2022-09-28 18:31
Viva Biotech Announced 2022 Interim Results 2022-08-29 23:55
Portfolio Highlights: Clinical and Financing Updates of AIxplorerBIO, Genhouse, VivaVision, Domain, Amberstone, Anji and QurAlis 2022-07-27 21:30
1